Ion Beam Applications, SA Share Price

Equities

IBAB

BE0003766806

Advanced Medical Equipment & Technology

Market Closed - Euronext Bruxelles 16:35:19 21/06/2024 BST 5-day change 1st Jan Change
13.72 EUR -2.83% Intraday chart for Ion Beam Applications, SA +2.69% +18.89%

Financials

Sales 2024 * 506M 541M 42.81B Sales 2025 * 574M 614M 48.58B Capitalization 400M 428M 33.87B
Net income 2024 * 11M 11.76M 930M Net income 2025 * 31M 33.14M 2.62B EV / Sales 2024 * 0.74 x
Net cash position 2024 * 27.97M 29.9M 2.37B Net cash position 2025 * 33.9M 36.24M 2.87B EV / Sales 2025 * 0.64 x
P/E ratio 2024 *
35.2 x
P/E ratio 2025 *
13.2 x
Employees 2,066
Yield 2024 *
2.08%
Yield 2025 *
3.02%
Free-Float 66.13%
More Fundamentals * Assessed data
Dynamic Chart
Ion Beam Applications SA Signs Contract with Yale New Haven Health and Hartford HealthCare to Install Proteus®?One Proton Therapy Solution in Connecticut, US CI
Ion Beam Applications SA completed the acquisition of all the assets of Radcal Corporation. CI
Ion Beam Applications SA to Recommend Dividend for 2023 CI
Transcript : Ion Beam Applications SA, 2023 Earnings Call, Mar 21, 2024
Ion Beam Applications SA Reports Earnings Results for the Full Year Ended December 30, 2023 CI
Ion Beam Applications Books Order for Electron Beam Irradiation System MT
Ion Signs Contract to Install Be-Efficient Irradiation Solution in Germany CI
Ion Beam Applications Bags Cyclotron Order MT
Bayer Strikes Supply Deal for Actinium Isotope with Belgian JV MT
Ion Beam Applications to Buy US-based Diagnostic X-ray Measurement Company Radcal MT
Ion Beam Applications SA signed an agreement to acquire all the assets of Radcal Corporation. CI
Ion Beam Applications Sa Announces the Cyclone 70 System Installed At the Ithemba Laboratory for Accelerator Based Sciences in Cape Town CI
Ion Beam Applications to Deliver Proton Therapy System to Poland's Health Technologies MT
IBA Signs Contract for a ProteusONE Proton Therapy System to be Located at the Greater Poland Cancer Center CI
Ion Beam Applications S.A., CMI Inc. and Life Molecular Imaging Announce Japanese Approval for the Reimbursement of Amyloid-Pet Diagnostic Neuraceq in Alzheimer's Disease CI
More news
1 day-2.83%
1 week+2.69%
Current month-4.59%
1 month-3.24%
3 months+10.47%
6 months+19.30%
Current year+18.89%
More quotes
1 week
12.90
Extreme 12.9
14.36
1 month
12.90
Extreme 12.9
14.54
Current year
9.31
Extreme 9.31
14.56
1 year
8.26
Extreme 8.26
16.68
3 years
8.26
Extreme 8.26
20.45
5 years
6.01
Extreme 6.01
20.45
10 years
6.01
Extreme 6.01
56.94
More quotes
Managers TitleAgeSince
Chief Executive Officer 56 31/12/95
Founder 76 27/03/86
Director of Finance/CFO 46 31/12/03
Members of the board TitleAgeSince
Chairman 63 31/12/86
Director/Board Member 77 30/04/17
Founder 76 27/03/86
More insiders
Date Price Change Volume
21/06/24 13.72 -2.83% 30,130
20/06/24 14.12 +6.01% 57,732
19/06/24 13.32 -3.34% 19,444
18/06/24 13.78 +5.84% 28,049
17/06/24 13.02 -2.54% 26,626

Real-time Euronext Bruxelles, June 21, 2024 at 04:35 pm

More quotes
Ion Beam Applications, SA (IBA) specializes in the design, manufacture, and marketing of cancer treatment and diagnosis equipment. Net sales break down by family of products as follows: - diagnosis and therapeutic treatment equipment and systems (84.8%): proton therapy equipment (62.5% of net sales; No. 1 worldwide), and particle accelerators (36.5%) used in the production of radioisotopes (cyclotrons) and in the development of sterilization and ionization solutions (Rhodotron® and Dynamitron®); - equipment and solutions of dosimetry (15.2%; No. 1 worldwide): measurement and analysis tools of the radiation doses in medical imaging and radiation therapy. Net sales are distributed geographically as follows: the United States (31.7%) and other (68.3%).
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
13.72 EUR
Average target price
17.5 EUR
Spread / Average Target
+27.55%
Consensus

Quarterly revenue - Rate of surprise